PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 80 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $868,550 | -29.7% | 83,756 | -2.9% | 0.00% | 0.0% |
| Q2 2023 | $1,235,744 | +81.9% | 86,295 | -9.3% | 0.00% | +50.0% |
| Q1 2023 | $679,492 | -38.1% | 95,167 | -2.7% | 0.00% | -50.0% |
| Q4 2022 | $1,097,080 | +14.2% | 97,779 | +12.8% | 0.00% | +33.3% |
| Q3 2022 | $961,000 | +29.7% | 86,688 | -1.3% | 0.00% | +50.0% |
| Q2 2022 | $741,000 | +22.9% | 87,840 | +98.3% | 0.00% | +100.0% |
| Q1 2022 | $603,000 | +105.8% | 44,300 | +197.3% | 0.00% | 0.0% |
| Q4 2021 | $293,000 | -38.7% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $478,000 | -5.2% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $504,000 | -10.0% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $560,000 | +13.1% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $495,000 | -19.1% | 14,900 | -10.8% | 0.00% | -50.0% |
| Q3 2020 | $612,000 | +11.3% | 16,700 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $550,000 | +27.6% | 16,700 | 0.0% | 0.00% | +100.0% |
| Q1 2020 | $431,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |